Center for Pharmacy Innovation and Outcomes
Medications are a primary therapeutic option for patients. Despite advances in treatments and growing evidence supporting best use, gaps in care related to medication use remain, resulting in substantial patient burden (cost, morbidity and mortality) and economic waste in an already stretched healthcare ecosystem. Within the modern healthcare environment, real-world evaluation studies provide evidence of effectiveness of therapy and gaps in care, new and evolving models of healthcare delivery offer hope of improved outcomes, and implementation of optimal and nimble models of care afford insight into improving medication use.
The Center for Pharmacy Innovation and Outcomes (CPIO) was established in 2015 in partnership with Geisinger’s Enterprise Pharmacy, which oversees system-wide medication use platforms in acute, ambulatory, community and managed care settings, and Geisinger’s Research enterprise. The CPIO mission is to conduct, implement, and disseminate research to optimize medication use by leveraging a highly evolved health IT infrastructure, applying robust data including patient-reported information and a growing genomic reservoir, and deploying trained and highly skilled clinical pharmacists.
The CPIO’s research focuses on meaningful improvement of population health management and value in healthcare as related to medication use. The CPIO uses scientific principles to evaluate and disseminate innovative pharmacy services, reduce the burden of medication nonadherence, pain and addiction, and personalize medicine through the application of pharmacogenomics.
- Scott Bolesta, PharmD, BCPS, FCCM
- Michael Gionfriddo, PharmD, PhD
- Jove Graham, PhD
- Dante Grassi, PharmD, BCPS
- Adam Gross, PharmD, CCRP
- Laney Jones, PharmD, MPH
- Rebecca Pulk, PharmD, MS
Selected Initiatives and Projects
Improving Transitional Care through Communication between Pharmacists
In an effort to cut the rate of preventable rehospitalizations for patients discharged from Geisinger facilities, researchers in the CPIO have initiated a study supported by the National Association of Chain Drug Stores Foundation evaluating the impact of pharmacist transmission of information from the inpatient to the outpatient setting on patient outcomes.
Pharmacist-led Familial Hypercholesterolemia Multidisciplinary Clinic
In collaboration with primary care providers and specialists at Geisinger, we are developing a patient and family member care process for our patients diagnosed with familial hypercholesterolemia. The Medication Therapy Disease Management (MTDM) pharmacists are providing medication reviews and adjustments to help patients reach their treatment goals.
Within the past 15 years, the United States has witnessed a 300 percent increase in the incidence of deaths due to prescription drug overdose. A common source of prescription drugs is the medicine cabinet where unused, unwanted or expired medications account for a large component of the abused supply. Geisinger has conveyed a Medication Take-Back team to lead a multi-disciplinary coalition dedicated to reducing the impact of unused, unwanted, expired medications on public health (namely drug addiction) and the environment through improved community awareness and increased convenience of proper medication disposal. Medication collection units are being placed at convenient locations throughout communities across the greater central and northeast region of Pennsylvania. CPIO researcher, Eric Wright is leading the effort to study the effects of the increased access to proper disposal. Learn more at: www.geisinger.org/takeback.
Geisinger Health System opened a pharmacist-led Medication Therapy Disease Management (MTDM) Chronic Pain Clinic in 2012 to help patients better manage their pain and identify/prevent addiction. The multidisciplinary clinic is comprised of administrators, primary care and interventional pain physicians, pharmacists, registered nurses and social workers/addiction counselors. Our goal is to help patients decrease their pain so they can reach important life goals.
Having a complete, accurate medication list that is transparent to healthcare providers and the patient is the principal goal in designing MedTrue™. In a multidisciplinary effort led by Eric Wright, MedTrue™ is a comprehensive medication adherence database and web-based application intended to serve as a single source for medication reconciliation, adherence monitoring and patient engagement support to help improve primary and secondary adherence.
Optimizing High-Cost Biologic Treatments for Patients with Multiple Sclerosis
Patients with multiple sclerosis (MS) will receive reliable delivery of the best practices designed by an evidence-based care path based on disease severity to deliver on the promise of value-based care. In addition, a 360-degree view of every MS patient is needed to assess the impact and quality of this program. Payers will be confident that their healthcare spending is well-stewarded and delivering on outcomes and preventing exacerbations that is important to patients and families. The infrastructure developed to manage high-cost biologics for MS, including the data capture applications, analytics and health IT tools, will be built to be scalable and extensible to enable efficient spread of this program to other high-cost therapeutics across the Geisinger Health System.